NDC-11 (Package) (Descending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
42291-0085-90 | 42291-0085 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Sept. 23, 2020 | In Use | ||
42291-0085-30 | 42291-0085 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | March 13, 2020 | In Use | ||
42291-0073-60 | 42291-0073 | ABIRATERONE | ABIRATERONE ACETATE | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | April 29, 2021 | In Use | |
42291-0072-01 | 42291-0072 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | April 14, 2023 | In Use | |
42291-0024-12 | 42291-0024 | Abiraterone | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jan. 14, 2019 | In Use | |
42291-0016-90 | 42291-0016 | ANASTROZOLE | ANASTROZOLE | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb. 6, 2023 | In Use | ||
42291-0016-30 | 42291-0016 | ANASTROZOLE | ANASTROZOLE | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb. 6, 2023 | In Use | ||
42254-0243-30 | 42254-0243 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 3, 2011 | In Use | ||
42254-0213-10 | 42254-0213 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 27, 2007 | In Use | |
42254-0212-10 | 42254-0212 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 27, 2007 | In Use |
Found 10,000 results in 9 milliseconds — Export these results